What is the appropriate management of hypercalcemia?

Management of Hypercalcemia

Hypercalcemia should be treated with intravenous hydration using normal saline followed by intravenous bisphosphonates (zoledronic acid 4 mg preferred) or denosumab, with additional agents like calcitonin, steroids, or loop diuretics added based on severity and underlying etiology. 1

Initial Assessment and Severity Stratification

The management approach depends on the severity and acuity of presentation:

• Mild hypercalcemia (corrected calcium <12 mg/dL or <3 mmol/L): Often asymptomatic but may cause fatigue and constipation in ~20% of patients 2
• Moderate to severe hypercalcemia (corrected calcium ≥12 mg/dL or ≥3 mmol/L): Presents with polyuria, polydipsia, nausea, confusion, vomiting, abdominal pain, and myalgia 1
• Severe hypercalcemia (corrected calcium >14 mg/dL or >3.5 mmol/L): Can cause mental status changes, bradycardia, hypotension, somnolence, and coma 1, 2

Treatment should be initiated at corrected serum calcium levels greater than 3.00 mmol/L (12 mg/dL) 1

Core Treatment Algorithm

Step 1: Hydration (First-Line for All Cases)

• Administer IV normal saline to maintain diuresis >2.5 L/day 1
• Rehydration with IV crystalloid fluids not containing calcium corrects hypercalcemia-associated hypovolemia and promotes calciuresis 1
• Oral hydration may be effective in mild hypercalcemia 1
• Loop diuretics (furosemide) should be given as needed only after correction of intravascular volume, not before 1

Step 2: Antiresorptive Therapy

For moderate to severe hypercalcemia:

• Zoledronic acid 4 mg IV is the preferred bisphosphonate, infused over 15 minutes in 100 mL volume to limit renal complications 1
• Zoledronic acid normalizes calcium in 50% of patients by day 4, compared to 33% with pamidronate 1
• Alternative bisphosphonates include pamidronate 90 mg IV over 2 hours or ibandronate 1
• The 8-mg dose of zoledronic acid should be reserved for relapsed or refractory cases 1

Denosumab as alternative:

• Subcutaneous denosumab 120 mg is effective, particularly in bisphosphonate-refractory cases 1, 3
• Denosumab lowered serum calcium in 64% (21/33) of patients with hypercalcemia refractory to recent IV bisphosphonate treatment within 10 days 1
• Denosumab is preferred in patients with renal disease due to lower rates of renal toxicity compared to zoledronic acid 1
• Monitor for hypocalcemia risk, which is higher with denosumab; start calcium and vitamin D supplements if necessary 1

Step 3: Adjunctive Therapies Based on Etiology and Severity

For severe or rapidly developing hypercalcemia:

• Calcitonin can be added to bisphosphonate or denosumab therapy for rapid short-term control 1
• Calcitonin provides faster onset but shorter duration of action compared to bisphosphonates 4

For hypercalcemia due to excessive intestinal calcium absorption:

• Glucocorticoids are primary treatment when hypercalcemia results from vitamin D intoxication, granulomatous disorders (sarcoidosis), or some lymphomas 1, 2
• Steroids are also part of the treatment armamentarium for multiple myeloma-related hypercalcemia 1

For refractory or recurrent cases:

• If hypercalcemia persists despite bisphosphonate therapy, switch to denosumab 5
• Consider retreatment with higher doses of zoledronic acid (8 mg) for patients who relapse or are refractory to prior therapy 1

Special Populations and Contexts

Malignancy-Related Hypercalcemia

• Hypercalcemia of malignancy occurs in 10-25% of cancer patients and is associated with poor prognosis (median survival ~1 month in lung cancer) 1
• The Endocrine Society strongly recommends treatment with either denosumab or IV bisphosphonate 5
• The Endocrine Society conditionally suggests using denosumab rather than IV bisphosphonate based on low certainty evidence 5
• Treatment of the underlying malignancy is instrumental for controlling hypercalcemia and preventing recurrence 5

Multiple Myeloma

• Hypercalcemia should be treated with hydration, bisphosphonates, denosumab, steroids, and/or calcitonin 1
• Among bisphosphonates, the NCCN panel prefers zoledronic acid for treatment of hypercalcemia in multiple myeloma 1

Parathyroid Carcinoma

• The Endocrine Society conditionally suggests treatment with either a calcimimetic or an antiresorptive agent (IV bisphosphonate or denosumab) 5

Renal Failure

• In patients with advanced kidney disease and refractory severe hypercalcemia, hemodialysis should be considered 4
• Denosumab may be indicated in patients with kidney failure as it has lower renal toxicity 2, 3

Monitoring Requirements

During bisphosphonate therapy:

• Monitor serum creatinine, urea, total calcium, and urinary albumin before and during treatment 1
• Discontinue bisphosphonates if:
  • Unexplained albuminuria >500 mg/24 hours
  • Increase in serum creatinine >0.5 mg/dL (44 μmol/L)
  • Absolute serum creatinine value >1.4 mg/dL (124 μmol/L) in patients with normal baseline 1

With denosumab:

• Monitor calcium levels post-treatment due to increased risk of hypocalcemia compared to zoledronic acid 1
• Provide calcium and vitamin D supplementation as needed 1

Common Pitfalls to Avoid

• Do not administer loop diuretics before adequate volume repletion, as this can worsen dehydration 1
• Do not use bisphosphonates as monotherapy without hydration, as IV fluids are essential first-line treatment 1
• Avoid rapid correction in severe chronic hypercalcemia, though this is less of a concern than with hyponatremia 1
• Do not overlook the underlying cause—treating hypercalcemia without addressing the primary disease (malignancy, hyperparathyroidism) will lead to recurrence 5
• Monitor renal function closely with bisphosphonates, as renal toxicity can occur at any time during therapy 1